Skip to main content

Advertisement

SpringerLink
Log in

Use of Clarithromycin and Adverse Cardiovascular Events among Older Patients Receiving Donepezil

A Population-Based, Nested Case-Control Study

  • Short Communication
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Background: Donepezil is a commonly used drug in older people that due to its procholinergic effects can provoke bradycardia and neurocardiogenic syncope. Donepezil is metabolized by the cytochrome P450 isozyme 3A4 (CYP3A4). Clarithromycin is a potent inhibitor of CYP3A4, and patients taking both of these drugs may be at increased risk of cardiac adverse events.

Objective: The aim of this study was to evaluate the association between recent use of clarithromycin and adverse cardiovascular events in elderly patients receiving donepezil.

Methods: A population-based, nested case-control study using provincial healthcare databases was conducted. The base cohort was made up of persons 66 years of age or older who were prescribed donepezil and also were prescribed clarithromycin, erythromycin, azithromycin, cefuroxime, moxifloxacin or levofloxacin. Cases were those members of the base cohort hospitalized for bradycardia, syncope or complete atrioventricular block. For each case patient, five controls were matched according to age, sex and residence (community or long-term care).

Results: Between July 2002 and March 2010, 17712 patients continuously receiving donepezil were prescribed one of the antibacterials. In 1400 person-years of follow-up, 59 cases were identified. As compared with azithromycin, there was no statistically significant association between use of clarithromycin in donepezil users and subsequent adverse cardiovascular events (odds ratio 0.67; 95% CI 0.28, 1.63). There was no significant risk associated with exposure to either cefuroxime or respiratory quinolones.

Conclusions: The use of clarithromycin in elderly donepezil users did not significantly increase the risk of adverse cardiovascular outcomes. However, our study cannot rule out a possible small increase in risk. Although anti-bacterials can be beneficial, care should be taken in selecting antibacterials for use in older people receiving donepezil.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II

References

  1. McLaren AT, Allen J, Murray A, et al. Cardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord 2003; 15(4): 183–8

    Article  PubMed  CAS  Google Scholar 

  2. Raschetti R, Maggini M, Sorrentino GC, et al. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer’s disease. Eur J Clin Pharmacol 2005; 61(5-6): 361–8

    Article  PubMed  CAS  Google Scholar 

  3. Park-Wyllie LY, Mamdani MM, Li P, et al. Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS Med 2009; 6(9): el000157

    Article  Google Scholar 

  4. Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving Cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 2009; 169(9): 867–73

    Article  PubMed  Google Scholar 

  5. Poluzzi E, Raschi E, Moretti U, et al. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepi-demiol Drug Saf 2009; 18(6): 512–8

    Article  CAS  Google Scholar 

  6. Takaya T, Okamoto M, Yodoi K, et al. Torsades de Pointes with QT prolongation related to donepezil use. J Cardiol 2009; 54(3): 507–11

    Article  PubMed  Google Scholar 

  7. Hernandez RK, Farwell W, Cantor MD, et al. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the Veterans Affairs New England healthcare system. J Am Geriatr Soc 2009; 57(11): 1997–2003

    Article  PubMed  Google Scholar 

  8. Yano R, Tani D, Watanabe K, et al. Evaluation of potential interaction between vinorelbine and clarithromycin. Ann Pharmacother 2009; 43(3): 453–8

    Article  PubMed  CAS  Google Scholar 

  9. Wright AJ, Gomes T, Mamdani MM, et al. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. CMAJ 2011; 183(3): 303–7

    Article  PubMed  Google Scholar 

  10. Loeb M, Simor AE, Landry L, et al. Antibiotic use in Ontario facilities that provide chronic care. J Gen Intern Med 2001; 16(6): 376–83

    Article  PubMed  CAS  Google Scholar 

  11. Hanlon JT, Sloane RJ, Pieper CF, et al. Association of adverse drug reactions with drug-drug and drug-disease interactions in frail older outpatients. Age Ageing 2011; 40(2): 274–7

    Article  PubMed  Google Scholar 

  12. Fischer HD, Juurlink DN, Mamdani MM, et al. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med 2010; 170(7): 617–21

    Article  PubMed  CAS  Google Scholar 

  13. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354(13): 1352–61

    Article  PubMed  CAS  Google Scholar 

  14. Gomes T, Mamdani MM, Juurlink DN. Macrolide-induced digoxin toxicity: a population-based study. Clin Pharmacol Ther 2009; 86(4): 383–6

    Article  PubMed  CAS  Google Scholar 

  15. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and Cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46Suppl. 1: 25–9

    PubMed  CAS  Google Scholar 

  16. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46Suppl. 1: 30–4

    PubMed  CAS  Google Scholar 

  17. Varsaldi F, Miglio G, Scordo MG, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patients. Eur J Clin Pharmacol 2006; 62(9): 721–6

    Article  PubMed  CAS  Google Scholar 

  18. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31(2): 383–421

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded by an Interdisciplinary Capacity Enhancement Grant (HOA-80075) from the Canadian Institutes of Health Research (CIHR) Institute of Gender and Health and the CIHR Institute of Aging and by a Team Grant (OTG-88591) from the CIHR Institute of Nutrition, Metabolism and Diabetes. J.R.H. is supported by a CIHR Vanier Canada Graduate Scholarship.

This study was conducted at the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.

All authors declare no conflicts of interest. The CIHR, ICES and MOHLTC had no role in the study design; the collection, analysis and interpretation of data; the writing of the report; or the decision to submit the paper for publication.

Author information

Authors and Affiliations

  1. Faculty of Medicine, University of Toronto, Toronto, ON, Canada

    Janine R. Hutson & Paula A. Rochon

  2. Sunnybrook Health Sciences Centre, Institute for Clinical Evaluative Sciences, Toronto, ON, Canada

    Hadas D. Fischer, Xuesong Wang, Andrea Gruneir, Nick Daneman, Sudeep S. Gill, Paula A. Rochon & Geoffrey M. Anderson

  3. Women’s College Research Institute, Women’s College Hospital, Toronto, ON, Canada

    Andrea Gruneir, Paula A. Rochon & Geoffrey M. Anderson

  4. Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada

    Andrea Gruneir, Paula A. Rochon & Geoffrey M. Anderson

  5. Department of Medicine, Queen’s University, Kingston, ON, Canada

    Sudeep S. Gill

Authors
  1. Janine R. Hutson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hadas D. Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xuesong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea Gruneir
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nick Daneman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sudeep S. Gill
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paula A. Rochon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Geoffrey M. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janine R. Hutson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hutson, J.R., Fischer, H.D., Wang, X. et al. Use of Clarithromycin and Adverse Cardiovascular Events among Older Patients Receiving Donepezil. Drugs Aging 29, 205–211 (2012). https://doi.org/10.2165/11599090-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11599090-000000000-00000

Keywords

Search

Navigation